The metabolic syndrome (MetS) has been shown to predict mortality in the middle-aged, but less is known on the impact of MetS and its components on mortality risk in the elderly. Our objectives were ( ) to examine the association of MetS with the risk of all-cause 1 and cause specific mortality in a French elderly community-dweller cohort; ( ) to determine the main components driving these 2 associations.
Introduction
The role of metabolic syndrome (MetS), defined as a cluster of metabolic abnormalities including obesity, hyperglycemia, dyslipidemia and hypertension, has been evidenced in the middle-age and pre-elderly ( ). Its role in mortality of the elderly has been 1 -7 less explored and led to mixed results ( ). 8 -12 As MetS is comprised of multiple components, it remains unclear whether the relation between MetS and mortality in the elderly is attributable to the MetS as a whole, or driven by some specific MetS components. Furthermore, while elevated risk factor levels are common and increasingly treated in older populations, it is also important to determine whether the use of hypertensive, anti-diabetic and lipids lowering drugs modifies the association between MetS and mortality. To increase understanding on these issues, we aimed to investigate the association of MetS and each of its components with the risk of overall mortality and cause specific mortality over 7-year whether the association is fully driven by some of the MetS components, or alternatively whether there is synergistic effect between the MetS components on mortality risk.
Participants and Methods
Data came from the French multicentre prospective Three-Cities-Study including originally 9294 community-dwelling persons aged 65 years or older recruited from electoral rolls of three French cities from 1999 to 2001 ( ). The study protocol was approved by the 13 were ascertained over the 7 years after the baseline examination. Information on the exact 13 Mortality and cause of death date and cause of death was obtained respectively from death registries and medical records (based on the International Classification of Diseases, version 10, ICD-10) ( ). Mortality from cardiovascular disease (CVD) (ICD-10: I and R960 codes) coronary heart disease 15
(CHD) (ICD-10: I20-25 and R960), stroke (ICD-10: I60-69), cancer (ICD-10: C) were analyzed ( ). 16
The associations of MetS and its components with the risk of mortality were determined by Cox proportional hazards regression in which age (in years) during the study was used as the time axis, with left truncation at age of study entry. 2). All analyses were conducted using SAS software, version 9 (SAS Institute).
Results
Characteristics of the 7118 participants included in the present analyses according to the presence of MetS are described in . Table 1 Association between MetS and all-cause and cause-specific mortality risk Among participants who died over the 7-year follow-up (n 575, 8.1 ), a higher prevalence of MetS was observed (21.2 vs. 13. glucose and use of anti-diabetic drugs were introduced separately in the same model. Our results showed that the significant association of FPG component of the MetS was due to the anti-diabetic drugs (HR 1.96, 95 CI:1.46 2.62) rather than the elevated blood glucose (HR = % -= the MetS-mortality risk and to assess in which extent they would have a synergistic effect on mortality risk, we calculated the percent attenuation of the association after adding each individual component separately to a model already including MetS ( ). Elevated Table 2 FBG attenuates the MetS-mortality risk by 37.7 , while low HDL-cholesterol and high triglycerides attenuate it by 10.8 and 3.7 % % % respectively). The percent of attenuation by including both elevated FBG and one of the lipid abnormalities was higher than the sum of the percent attenuation of each of these components alone, suggesting that elevated FBG potentiates the lipid abnormality risk of mortality (
). To further investigate this synergistic effect, we used a backward elimination approach that removed all of the 5-, 4-, 3-, and Table 2 2-way interaction terms with > 0.05 from a saturated model that included all of the MetS components and their interaction terms. P Non-significant main effects were retained when interactions were significant.. A significant interaction (p 0.03) was found between = elevated FBG, high triglyceride and low HDL cholesterol. To quantify specifically the combined effects of these three components on all-cause mortality risk, a unique variable combining elevated FBG, high triglyceride, and low HDL cholesterol components was constructed we showed that participants with all these three components (n 113) were at a greater risk of all cause mortality (HR 2.66, 95 = = CI:1.71 4.13) compared to those with none of these components.
% -

Conclusion
The present study, carried out over 7-year follow-up, in a large elderly general population provides an empirical argument to support
MetS as a risk factor for all-cause mortality in the elderly. by showing evidence that specific components of MetS acted synergistically such that having elevated fasting blood glucose potentiates the impact of high triglyceride and low HDL-cholesterol on mortality risk, This predictive role of MetS on mortality risk was found to be independent of treatment for hypertension, dyslipidemia and hyperglycemia
The observed 50 excess risk of all-cause mortality associated with the MetS is in accordance with other prospective epidemiological % studies conducted in Finnish ( ), US ( ) and Italian ( ) elderly populations. Our findings on MetS components are also consistent with 11 9 12 previous reports carried out on middle-aged or elderly population, suggesting the predictive association of elevated FBG ( , , , , 1 -3 5 7 9 , ) and high triglyceride components ( , ) with mortality risk. The supremacy of FPG over other MetS components in predicting 11 12 2 7 mortality has been investigated, and our results suggest that the increased risk of mortality is associated with diabetes status (assessed by use of anti-diabetic drugs) but not with the elevated fasting blood glucose. In some studies, hypertension has been postulated to be a strong predictor of mortality ( , , , ) whereas other studies emphasize the consistent association between obesity measures and mortality 2 3 5 9 risk ( ). We did not find an increased mortality risk associated with either condition. The overall high prevalence of hypertension in the 17 elderly may be one explanation. There is also evidence that obesity is less marked a risk factor for mortality at older ages and among those with chronic conditions. Indeed, meta-analysis combining data from 40 cohort studies and including more than 250,152 patients with coronary artery disease, sustained the obesity paradox by showing that higher body mass index has been associated with reduced rather Finland, the BUPA Foundation, the UK, and the National Heart, Lung, and Blood Institute (R01HL036310-20A2) and the National Institute on Aging (R01AG034454-01), NIH, US.
Footnotes:
Reprint requests should be addressed to Tasnime Akbaraly
The funders had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
The authors have nothing to disclose. Disclosure Statement:
Contributors: KR, PBG, CT, CB, MLA designed the study; TNA conducted the statistical analyses and co-wrote the initial and final drafts, and is guarantor. MK, MLA, TM, PBG, CT, JT, KR, and CB co-wrote the final draft. MK AND MLA participated equally to the work 
